Overview

Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients

Status:
Recruiting
Trial end date:
2028-10-01
Target enrollment:
Participant gender:
Summary
Trial evaluating the impact on efficacy of mifamurtide as add-on treatment to post-operative chemotherapy compared to post-operative chemotherapy alone in first-line treatment of patients with high-risk osteosarcoma (defined as metastatic osteosarcoma at diagnosis or localised osteosarcoma with poor histological response).
Phase:
Phase 2
Details
Lead Sponsor:
UNICANCER
Treatments:
Acetylmuramyl-Alanyl-Isoglutamine
Mifamurtide